

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MAR 14 2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: March 14, 2003

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/081,185
Filing Date	02/25/2002
First Named Inventor	Thomas Dag Horn et al.
Group Art Unit	1642
Examiner Name	Unassigned

Attorney Docket Number 023533-0144

MAR 20 2003

RECEIVED
TECH CENTER 1900
MAY 20 2003
RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
GN	A1	JOHNSON ET AL., "Intralesional Injection of Mumps or <i>Candida</i> Skin Test Antigens; A Novel Immunotherapy for Warts," <i>Arch. Dermatol.</i> (Apr. 2001), Vol. 137, pp. 451-455.	
	A2	PHILLIPS ET AL., "Treatment of Warts with <i>Candida</i> Antigen Injection," <i>Archives of Dermatology</i> (October 2001), full paper, 7 pages.	
	A3	PHILLIPS ET AL., "Treatment of Warts with <i>Candida</i> Antigen Injection," <i>Arch. Dermatol.</i> (October 2000), Vol. 136, pp. 1274-1275, Vignette.	
	A4	SIGNORE, Letter commenting on "Candida Immunotherapy of Warts," <i>Arch. Dermatol.</i> (Sept. 2001), Vol. 137, pp. 1250-1251.	
	A5	HARADA, "Clinical application of fungus extracts and their culture filtrates in the treatment of skin diseases: Candida vaccine in the treatment of warts," <i>The Japanese Journal of Dermatology (Nippon Hifuka Gakkai Zashi)</i> (1979), Vol. 89, No. 6, pp. 397-402.	
	A6	MCCONAHY, "Common Warts: Immunity as a Result of Therapy," <i>CUTIS</i> (February 1976), Vol. 17, pp. 301-304.	
	A7	GREENSHER, "The Treatment of Warts with Mumps Skin Test Antigen," <i>Society of Teachers of Family Medicine</i> , 9 pages.	
	A8	GREENSHER, "Treatment of Laryngeal Papillomas with Mumps Skin Test Antigen," <i>The Lancet</i> (October 25, 1980), pp. 920-921.	
	A9	NAYLOR ET AL., "Contact immunotherapy of resistant warts," <i>Journal of the American Academy of Dermatology</i> (Oct. 1988), Vol., 19, No. 4, pp. 679-683, Abstract.	

Examiner Signature	<i>Sam B. Nickol</i>	Date Considered	7/13/04
--------------------	----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

MAR 14 2003

JCT09

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: March 14, 2003

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/081,185
Filing Date	02/25/2002
First Named Inventor	Thomas Dag Horn et al.
Group Art Unit	1642
Examiner Name	Unassigned

Attorney Docket Number 023533-0144

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GW	A10	PARSAD ET AL., "Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children," <i>Pediatric Dermatology</i> (Jul.-Aug. 2001), Vol. 18, No. 4, pp. 349-352, Abstract.	
	A11	AVENTIS PASTEUR, "Mumps Skin Test Antigen USP," Product Information Brochure as of February 1997, 2 pages.	
	A12	CANDIN®, Package Insert Text, 8 pages.	

TECH CENTER 1600/2900

MAR 20 2003

RECEIVED

Examiner
Signature*Mary B. Nickle*Date
Considered

7/13/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE		ATTY. DOCKET NO.	SERIAL NO.		
(MODIFIED)		PATENT AND TRADEMARK OFFICE		023533/0144	unassigned		
INFORMATION DISCLOSURE CITATION				APPLICANT			
				Thomas HORN, et al.			
Date Submitted to PTO: February 25, 2002				FILING DATE	GROUP ART UNIT		
				February 25, 2002	1642		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
<i>GW</i>	A1	5,662,903	09/02/1997	BOYER et al.			
<i>GW</i>	A2	6,123,948	09/26/2000	Whittle et al.			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>GW</i>	A3	AMER et al.	"Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts," <i>J. Amer. Acad. Dermatol.</i> , 18(15):1313-6 (1988)				
	A4	BAKER et al.	"Therapeutic Approaches to Papillomavirus Infections," <i>Infectious Diseases in Dermatology</i> , 15(2):331-340 (1997)				
	A5	BOLIN	<i>Equine Disease Quarterly</i> , Vol. 7, No. 3 (April 1999)				
	A6	BRODELL et al.	"The Treatment of Palmar and Plantar Warts Using Natural Alpha Interferon and a Needleless Injector," <i>Dermatol Surg.</i> , 21:213-218 (1995) ©Elsevier Science, Inc.				
	A7	GRIER et al.	"Regression of Cutaneous Melanosarcoma Following Intralesional Mycobacterium bovis BCG Injection: A Case Report," <i>J. of American Animal Hospital Association</i> , 14:76-81 (1978).				
	A8	HORN, Thomas	"Intradermal Skin Testing and Treatment with Candida and Mumps Antigens of <i>Verruca Vulgaris</i> ," Dialog Abstract No. 121478 dated June 25, 1998.				
	A9	JOHANSSON et al.	"Dinitrochlorobenzene (DNCB) Treatment of Viral Warts," <i>Acta Derm Venereol</i> , 64:529-533 (1984).				
	A10	JOHNSON et al.	"Warts: A Guide to Their Removal," <i>Consultant</i> 39(1):253-266 (1999).				
	A11	KLEIN et al.	"Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial," <i>Cancer Immunol Immunother</i> 21:133-140 (1986) © Springer-Verlag				
	A12	LANDOW, Ken	"Nongenital warts, When is treatment warranted?," <i>Postgraduate Medicine</i> , 99(3):245-249 (1996)				
	A13	MILLER, et al.	"Human Papillomavirus Infection: Treatment Options for Warts," <i>American Family Physician</i> 53(1):135-143 (1996)				
	A14	MILLER et al.	Ophthalmic Surg., Vol. 25, NO. 8, abstract only (1994)				
	A15	MOND et al.	Abstract of WO 95/13089 (1995)				
	A16	NAPLES, et al.	"Verruca Vulgaris: Treatment with Natural Interferon Alfa Using a Needleless Injector," <i>Arch Dermatol</i> , 129:698-700 (1993)				
	A17	NAYLOR et al.	"Contact Immunotherapy of Resistant Warts," <i>J. Am Acad Dermatol</i> , 19:679-83 (1988)				
	A18	NELSON, Nancy	"Cancer Vaccines, Disappointing in the Past, Show Promise," <i>J. of the National Cancer Institute</i> , 88(8):486-488 (1996)				
	A19	PFISTER et al.	"Role of HPV in Cutaneous Premalignant and Malignant Tumors," <i>Clinics in Dermatology</i> , 15:335-347 (1997) ©Elsevier Science Inc., New York, New York.				
	A20	QUAN et al.	"The role of human papillomavirus in carcinoma," <i>J. Am Acad Dermatol.</i> , 25(4):698-705 (1991)				
EXAMINER			DATE CONSIDERED				
<i>Mary Bonnard</i>			7/13/04				
<p>* EXAMINER: Initial if citation is considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include any copy of this form with next communication to applicant.</p>							